Clinical Trial

Showing results 51 - 60 of 69

Sorted by most recent

TitleAuthorDate

A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial)

Tommaso Grassi, Andrea Mariani, David Cibula, Pamela T Soliman, Vera J Suman, Amy L Weaver, Silvana Pedra Nobre, Britta Weigelt, Gretchen E Glaser, Serena Cappuccio, Nadeem R Abu-Rustum

22 July 2020

Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE)

Roni Nitecki, Jose Alejandro Rauh-Hain, Alexander Melamed, Giovanni Scambia, Rene Pareja, Robert L Coleman, Pedro T Ramirez, Anna Fagotti

20 July 2020

Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol

Anette Stolberg Kargo, Angela Coulter, Kristina Lindemann, Pernille Tine Jensen, Niels Henrik Hjøllund, Berit Jul Mosgaard, Karina Dahl Steffensen

24 June 2020

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

Natalie YL Ngoi, Valerie Heong, Samuel Ow, Wen Yee Chay, Hee Seung Kim, Chel Hun Choi, Geraldine Goss, Jeffrey C Goh, Bee Choo Tai, Diana GZ Lim, Nivashini Kaliaperumal, Veonice B Au, John E Connolly, Jae-Weon Kim, Michael FriedlanderSee the full list of authors

25 June 2020

CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study

Jyoti Mayadev, Ana T Nunes, Mary Li, Michelle Marcovitz, Mark C Lanasa, Bradley J Monk

23 May 2020

Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial

Simone Koole, Ruby van Stein, Karolina Sikorska, Desmond Barton, Lewis Perrin, Donal Brennan, Oliver Zivanovic, Berit Jul Mosgaard, Anna Fagotti, Pierre-Emmanuel Colombo, Gabe Sonke, W J van Driel, , on behalf of the OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group, N BakrinSee the full list of authors

23 March 2020

Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

Jyoti Mayadev, Dmitriy Zamarin, Wei Deng, Heather Lankes, Roisin O'Cearbhaill, Carol A Aghajanian, Russell Schilder

22 December 2019

An exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA study): a randomized controlled pilot trial

Tabea Maurer, Julia von Grundherr, Stefan Patra, Anna Jaeger, Heiko Becher, Barbara Schmalfeldt, Birgit-Christiane Zyriax, Jenny Chang-Claude

2 December 2019

Oncologic outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of lymph node positivity; ABRAX (ABandoning RAd hyst in cerviX cancer)

Lukas Dostalek, Ingo Runnebaum, Francesco Raspagliesi, Ignace Vergote, Ladislav Dusek, Jiri Jarkovsky, David Cibula

20 November 2019

A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)

Juan Francisco Grau, Lorena Farinas-Madrid, Ana Oaknin

23 October 2019

Prev 1 2 3 4 567 Next